7th Apr 2015 14:39
Venn Life Sciences Holdings Plc
("Venn" or the "Company")
Notification of Shareholding
Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, has been informed by David Newton that he holds 2,200,000 ordinary shares of 0.1 pence each, representing 5.61 per cent. of the Company's issued share capital.
Enquiries:
| |
Venn Life Sciences Holdings Plc | |
Tony Richardson, Chief Executive Officer | Tel: +353 154 99 341 |
Zeus Capital Limited (Nominated Adviser and Broker) | |
Ross Andrews/Andrew Jones | Tel: 0161 831 1512 |
Alex Davies
| Tel: 020 7533 7727 |
Walbrook PR Ltd
Paul McManus | Tel: 020 7933 8787 or venn@walbrookpr.com Mob: 07980 541 893 |
Lianne Cawthorne | Mob: 07584 391 303 |
Related Shares:
ORPH.L